In the article by Rao et al, “A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction,” which published online on August 27, 2022, and appears in the October 18, 2022, issue of the journal (Circulation. 2022;146:1196–1206. doi: 10.1161/CIRCULATIONAHA.122.061612), a correction is needed.

In the Supplemental Material, in Table S2, the number of participants in the asundexian 20 mg group with chest pain was changed from 21 to 32. The original 8.1% was correct.

The authors regret this error.

The correction has been made to the current online version of the article, which is available at https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061612.

在 Rao 等人的文章中，“口服因子 XIa 抑制剂 Asundexian 预防急性心肌梗死后不良心血管结果的多中心、2 期、随机、安慰剂对照、双盲、平行组、剂量探索试验”， ”，于 2022 年 8 月 27 日在线发布，并出现在 2022 年 10 月 18 日的期刊 ( Circulation . 2022;146:1196–1206.doi: 10.1161/CIRCULATIONAHA.122.061612) 中，需要更正。

在补充材料中，在表 S2 中，asundexian 20 mg 胸痛组的参与者人数从 21 人变为 32 人。原来的 8.1% 是正确的。

作者对这个错误感到遗憾。

已对文章的当前在线版本进行了更正，可在 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061612 获取。